Elutia

Elutia General Information

Elutia has commercialized two main product lines—CanGaroo and SimpliDerm—both leveraging its proprietary drug-eluting biomaterial platform. CanGaroo provides an acellular envelope for cardiac devices to reduce infection and fibrotic response; SimpliDerm serves as a human acellular dermal matrix for soft tissue repair. The company’s new product, EluPro, recently received FDA clearance and competes directly with Medtronic’s TYRX in the antibiotic-eluting envelope market. Clinical data suggest that using natural biologics instead of synthetic polymers leads to better remodeling into healthy tissue and less scar formation.

Contact Information